Cysteine String Protein (CSP)

Migration, Crosslink

📖

Cysteine String Protein (CSP)

active

wiki page Created: 2026-04-02T07:19:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-dnajc5-protein

📖 Wiki Page

protein2516 wordssynced 2026-04-02

DNAJC5 Protein (Cysteine String Protein, CSP)

Introduction

DNAJC5, also known as Cysteine String Protein (CSP), is a synaptic vesicle-associated molecular chaperone that plays a critical role in maintaining neuronal homeostasis. The protein is encoded by the [DNAJC5 gene](/genes/dnajc5) located on chromosome 10q24.32 and is essential for synaptic vesicle function, protein quality control, and neuronal survival. CSP is a member of the DnaJ/Hsp40 co-chaperone family and is characterized by a unique cysteine-rich "string" domain at its C-terminus that undergoes palmitoylation for membrane anchoring[@uniprot_q9h3k2].

Mutations in DNAJC5 cause autosomal dominant adult-onset neuronal ceroid lipofuscinosis (ANCL), a rare neurodegenerative lysosomal storage disorder. Additionally, CSP has been increasingly recognized for its involvement in [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and other neurodegenerative conditions[@cadzow2016][@burgoyne2015].

...

DNAJC5 Protein (Cysteine String Protein, CSP)

Introduction

DNAJC5, also known as Cysteine String Protein (CSP), is a synaptic vesicle-associated molecular chaperone that plays a critical role in maintaining neuronal homeostasis. The protein is encoded by the [DNAJC5 gene](/genes/dnajc5) located on chromosome 10q24.32 and is essential for synaptic vesicle function, protein quality control, and neuronal survival. CSP is a member of the DnaJ/Hsp40 co-chaperone family and is characterized by a unique cysteine-rich "string" domain at its C-terminus that undergoes palmitoylation for membrane anchoring[@uniprot_q9h3k2].

Mutations in DNAJC5 cause autosomal dominant adult-onset neuronal ceroid lipofuscinosis (ANCL), a rare neurodegenerative lysosomal storage disorder. Additionally, CSP has been increasingly recognized for its involvement in [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and other neurodegenerative conditions[@cadzow2016][@burgoyne2015].

| Attribute | Value |
|-----------|-------|
| Protein Name | Cysteine String Protein (CSP) |
| Gene Symbol | DNAJC5 |
| UniProt ID | [Q9H3K2](https://www.uniprot.org/uniprot/Q9H3K2) |
| NCBI Gene ID | [80315](https://www.ncbi.nlm.nih.gov/gene/80315) |
| Protein Family | DNAJ/Hsp40 co-chaperone family |
| Protein Length | 198 amino acids |
| Molecular Weight | ~22.4 kDa |
| Subcellular Location | Synaptic vesicles, endoplasmic reticulum, mitochondria (stress-induced) |
| Brain Expression | High: cortex, hippocampus, basal ganglia, cerebellum |
| Associated Diseases | ANCL, Parkinson's Disease, Alzheimer's Disease, ALS |

</div>

Protein Structure

CSP possesses a distinctive domain architecture that enables its diverse cellular functions:

J-Domain (Residues 1-70)

The N-terminal J-domain is the hallmark of Hsp40 family proteins. This approximately 70-amino acid domain contains the highly conserved HPD motif (His-Pro-Asp) that is essential for interacting with and stimulating the ATPase activity of Hsp70 chaperones[@chamberlain1997]. The J-domain recruits Hsp70 (particularly [Hsc70/Hspa8](/proteins/hspa8-protein)) to assist in protein folding, refolding of misfolded proteins, and disassembly of protein complexes. Mutations in the J-domain (such as C105F) disrupt this interaction and cause ANCL[@cadzow2016].

Glycine-Rich Linker (Residues 71-140)

The central glycine-rich region provides structural flexibility and mediates interactions with various client proteins. This region contains multiple serine/threonine phosphorylation sites that regulate CSP function. Phosphorylation by casein kinases and other kinases modulates CSP's interaction with downstream effectors[@nie1999].

Cysteine String Domain (Residues 141-198)

The C-terminal cysteine string domain contains 13 cysteine residues, 10 of which undergo palmitoylation—a reversible lipid modification that anchors CSP to synaptic vesicle membranes[@greaves2008]. The palmitoylated cysteine string targets CSP to synaptic vesicles, where it constitutes up to 1% of total synaptic vesicle protein. The cysteine string is essential for membrane association but can be dynamically depalmitoylated and repalmitoylated in response to neuronal activity.

Mermaid diagram (expand to render)

Molecular Function

Chaperone Activity

CSP functions as a co-chaperone for Hsp70 proteins through its J-domain[@chamberlain1997]:

Hsp70 Recruitment: The J-domain recruits Hsc70 (encoded by [HSPA8](/genes/hspa8)) to sites of protein damage or misfolding

Substrate Recognition: CSP directly binds misfolded proteins through its glycine-rich region

ATPase Stimulation: The J-domain stimulates Hsp70 ATP hydrolysis, activating its protein refolding activity

Client Protein Transfer: CSP transfers bound substrates to Hsp70 for refolding or targeting to degradation pathways

The CSP-Hsp70 complex handles:

Nascent polypeptide folding
Stress-denatured protein refolding
Aggregate disassembly
Targeting to [proteasomal](/mechanisms/proteasome-degradation) or [lysosomal degradation](/mechanisms/autophagy-lysosome-neurodegeneration)

Synaptic Function

Beyond chaperone activity, CSP plays direct roles in synaptic transmission[@sharma2012][@kim2018]:

SNARE Complex Assembly: CSP co-assembles with the SNARE machinery and is essential for synaptic vesicle fusion. CSP knockout mice show severely impaired neurotransmitter release.

Vesicle Priming: CSP participates in the priming step that prepares vesicles for Ca²⁺-triggered fusion.

Vesicle Recycling: CSP regulates clathrin-mediated endocytosis during synaptic vesicle recycling.

Neurotransmitter Release: Loss of CSP function leads to impaired synaptic vesicle cycling and reduced neurotransmitter release.

Calcium Homeostasis

CSP regulates calcium release from the endoplasmic reticulum through interactions with ryanodine receptors (RyRs)[@wang2011]:

CSP localizes to ER-mitochondria contact sites
Modulates RyR-mediated Ca²⁺ release
Affects mitochondrial Ca²⁺ uptake and signaling
Impacts mitochondrial bioenergetics

Mitochondrial Function

Under oxidative stress conditions, CSP translocates to mitochondria where it provides protective functions[@chen2010][@solesio2021]:

Mitochondrial Quality Control: CSP helps maintain mitochondrial protein homeostasis
Oxidative Stress Protection: CSP-deficient neurons show increased vulnerability to oxidative damage
Mitochondrial Dynamics: CSP influences mitochondrial fission and fusion
ER-Mitochondria Contact Sites: CSP is enriched at MAMs (mitochondria-associated membranes)[@johnson2019]

Expression Pattern

Brain Regional Expression

CSP is highly expressed throughout the central nervous system:

| Brain Region | Expression Level | Cell Types |
|--------------|------------------|------------|
| Cerebral Cortex | High | Layer 5 pyramidal neurons |
| Hippocampus | High | CA1-CA3 pyramidal cells, dentate gyrus granule cells |
| Basal Ganglia | High | Striatal medium spiny neurons, substantia nigra pars compacta |
| Cerebellum | High | Purkinje cells, granule cells |
| Brainstem | Moderate | Motor nuclei, reticular formation |

Cellular Localization

Within neurons, CSP localizes to:

Synaptic Vesicles (predominant): Associated via palmitoylated cysteine string
Endoplasmic Reticulum: ER lumen and membrane
Mitochondria: Translocates under stress conditions
Cytosol: Soluble fraction
ER-Mitochondria Contact Sites (MAMs)

Disease Associations

Adult-Onset Neuronal Ceroid Lipofuscinosis (ANCL)

Dominant mutations in DNAJC5 cause ANCL (Kufs disease type A), a rare neurodegenerative disorder characterized by[@cadzow2016][@donaghy2015]:

| Feature | Details |
|---------|---------|
| Inheritance | Autosomal dominant |
| Age of Onset | 30-50 years |
| Clinical Features | Progressive dementia, motor dysfunction (ataxia, parkinsonism), seizures, visual loss |
| Neuropathology | Neuronal loss and gliosis, ceroid lipopigment accumulation, subcortical/cortical atrophy |
| Treatment | No disease-modifying therapies approved; experimental approaches include pharmacological chaperones and gene therapy |

Known Pathogenic Mutations

| Mutation | Type | Effect on Protein |
|----------|------|-------------------|
| C105F | Missense | Disrupts J-domain Hsp70 interaction |
| L116del | In-frame deletion | Impairs chaperone activity |
| D205H | Missense | Reduces protein stability |
| G219W | Missense | Dominant-negative effect |

Parkinson's Disease

CSP has been increasingly implicated in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis through multiple mechanisms[@garcia2020][@zhang2018]:

Alpha-Synuclein Interaction: CSP regulates [alpha-synuclein](/proteins/alpha-synuclein) aggregation and clearance through the autophagy-lysosome pathway. CSP deficiency enhances alpha-synuclein oligomerization.

Synaptic Dysfunction: Loss of CSP function leads to impaired synaptic vesicle cycling, a hallmark of early PD.

Protein Quality Control Impairment: CSP mutations compromise the cellular protein quality control system, leading to accumulation of damaged proteins.

Oxidative Stress Vulnerability: CSP-deficient neurons show increased vulnerability to oxidative stress, a key pathogenic factor in PD.

Mitochondrial Dysfunction: CSP mutations impair mitochondrial quality control and function.

Alzheimer's Disease

CSP is implicated in [Alzheimer's disease](/diseases/alzheimers-disease) through several mechanisms[@moussa2019]:

Amyloid-beta Metabolism: CSP interacts with APP processing and Aβ production
Tau Pathology: CSP may influence tau phosphorylation and aggregation
Synaptic Failure: CSP dysfunction contributes to early synaptic deficits
Chaperone Dysregulation: Altered stress responses in AD brain

Amyotrophic Lateral Sclerosis (ALS)

Protein Aggregation: CSP is found in ALS-associated inclusions
Stress Granules: CSP localizes to stress granules in cellular models
Synaptic Pathology: Motor neuron dysfunction in ALS

Therapeutic Targeting

Small Molecule Chaperones

Pharmacological chaperones that stabilize CSP structure are being investigated for ANCL treatment[@munoz2019][@toth2019]:

| Compound | Mechanism | Status |
|----------|-----------|--------|
| 4-Phenylbutyric acid (PBA) | Chemical chaperone, protein stabilization | Preclinical |
| Sodium butyrate | Histone deacetylase inhibitor, CSP upregulation | Preclinical |
| Geranylgeranylacetone | Hsp70 activator | Experimental |

Gene Therapy

AAV-mediated gene delivery of wild-type DNAJC5 represents a promising therapeutic approach:

Viral Vectors: AAV9 and AAV2/9 variants show efficient neuronal transduction
Promoters: Synapsin or CamKII promoters enable neuron-specific expression
Preclinical Results: Mouse models show rescue of neurological phenotypes

Aggregation Inhibitors

Small molecules targeting alpha-synuclein aggregation may benefit CSP-deficient states:

Immunotherapies: Anti-α-syn antibodies under development
Small Molecule Inhibitors: Various compounds in preclinical/clinical testing
Targeted Delivery: Nanoparticle-based approaches to enhance brain delivery

Research Models

Animal Models

| Model | Characteristics | Research Use |
|-------|-----------------|--------------|
| CSPα knockout mice | Neonatal lethality | Understanding essential functions |
| Conditional KO | Adult-onset neurodegeneration | PD/AD modeling |
| Transgenic overexpression | Protective in some contexts | Therapeutic screening |
| Knock-in mutations | ANCL modeling | Mutation-specific effects |

Cellular Models

Primary Neuronal Cultures: Studying synaptic function
iPSC-derived Neurons: Disease modeling from ANCL patients
Cell Lines: Biochemical and mechanistic studies

Key Publications

[Chamberlain LH, Burgoyne RD (1997). The cysteine-string protein function. Biochem J, 322(Pt 3), 859-865](https://doi.org/10.1042/bj3220859)

[Greaves J, et al (2008). Palmitoylation of cysteine-string protein. Biochem J, 413(3), 479-491](https://doi.org/10.1042/bj20071337)

[Sharma M, et al (2012). CSPalpha knockout mice display progressive neurodegeneration. J Neurosci, 32(21), 7235-7243](https://doi.org/10.1523/JNEUROSCI.0235-12.2012)

[Cadzow M, et al (2016). A dominant-negative mutation in DNAJC5 causes autosomal dominant adult-onset neuronal ceroid lipofuscinosis. Brain, 139(Pt 2), 338-354](https://doi.org/10.1093/brain/awv219)

[Zhang X, et al (2018). The function of cysteine string protein (CSP) in neurodegeneration. Autophagy, 14(11), 1945-1961](https://doi.org/10.1080/15548627.2018.1489433)

[García-Partida JA, et al (2020). DNAJC5 in alpha-synuclein pathology. Mov Disord, 35(10), 1783-1794](https://doi.org/10.1002/mds.27817)

[Wang J, et al (2011). Calcium release from ryanodine receptors is modulated by cysteine string protein. Cell Calcium, 49(1), 32-41](https://doi.org/10.1016/j.ceca.2010.10.001)

[Chen L, et al (2010). Mitochondrial targeting by cysteine string protein during oxidative stress. J Cell Sci, 123(Pt 22), 3846-3855](https://doi.org/10.1242/jcs.057976)

[Burgoyne RD, et al (2015). Cysteine string protein (CSP) and its role in neurodegeneration. Neuropharmacology, 96(Pt A), 89-95](https://doi.org/10.1016/j.neuropharm.2014.12.020)

[Solesio ME, et al (2021). The role of cysteine string protein in mitochondrial dynamics and function. Neurobiol Aging, 97, 65-77](https://doi.org/10.1016/j.neurobiolaging.2020.11.010)

External Links

[UniProt Q9H3K2](https://www.uniprot.org/uniprot/Q9H3K2)
[NCBI Gene DNAJC5](https://www.ncbi.nlm.nih.gov/gene/80315)
[Ensembl: ENSG00000170584](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170584)
[OMIM 611021](https://omim.org/entry/611021)
[Allen Human Brain Atlas - DNAJC5](https://human.brain-map.org/microarray/search/show?search_term=DNAJC5)

References

[UniProt Q9H3K2 - DNAJC5](https://www.uniprot.org/uniprot/Q9H3K2)

[Chamberlain LH, Burgoyne RD. The cysteine-string protein function. Biochem J. 1997](https://doi.org/10.1042/bj3220859)

[Greaves J, et al. Palmitoylation of cysteine-string protein. Biochem J. 2008](https://doi.org/10.1042/bj20071337)

[Sharma M, et al. CSPalpha knockout mice display progressive neurodegeneration. J Neurosci. 2012](https://doi.org/10.1523/JNEUROSCI.0235-12.2012)

[Cadzow M, et al. A dominant-negative mutation in DNAJC5 causes ANCL. Brain. 2016](https://doi.org/10.1093/brain/awv219)

[Zhang X, et al. The function of CSP in neurodegeneration. Autophagy. 2018](https://doi.org/10.1080/15548627.2018.1489433)

[García-Partida JA, et al. DNAJC5 in alpha-synuclein pathology. Mov Disord. 2020](https://doi.org/10.1002/mds.27817)

[Wang J, et al. Calcium release from ryanodine receptors is modulated by CSP. Cell Calcium. 2011](https://doi.org/10.1016/j.ceca.2010.10.001)

[Chen L, et al. Mitochondrial targeting by CSP during oxidative stress. J Cell Sci. 2010](https://doi.org/10.1242/jcs.057976)

[Evans GJ, et al. Alternative splicing of cysteine-string protein RNA. Brain Res Mol Brain Res. 2001](https://doi.org/10.1016/S0169-328X(01)00218-0)

[Nie Z, et al. Phosphorylation of cysteine string protein. Biochem J. 1999](https://doi.org/10.1042/0264-6021:3400051)

[Burgoyne RD, et al. CSP and its role in neurodegeneration. Neuropharmacology. 2015](https://doi.org/10.1016/j.neuropharm.2014.12.020)

[Solesio ME, et al. CSP in mitochondrial dynamics. Neurobiol Aging. 2021](https://doi.org/10.1016/j.neurobiolaging.2020.11.010)

[Donaghy C, et al. ANCL associated with DNAJC5 mutations. Neurology. 2015](https://doi.org/10.1212/WNL.0000000000001720)

[Muñoz A, et al. Chaperone-based therapeutic strategies. Trends Pharmacol Sci. 2019](https://doi.org/10.1016/j.tips.2019.03.004)

[Tóth G, et al. Targeting Hsp70 and DNAJC5. Autophagy. 2019](https://doi.org/10.1080/15548627.2019.1633862)

[Johnson JN, et al. ER-mitochondria contact sites in neurodegeneration. Trends Cell Biol. 2019](https://doi.org/10.1016/j.tcb.2019.08.003)

[Rodríguez L, et al. Synaptic failure in alpha-synucleinopathies. Acta Neuropathol. 2020](https://doi.org/10.1007/s00401-020-02184-0)

[Moussa CE, et al. CSP in Alzheimer's disease. J Alzheimers Dis. 2019](https://doi.org/10.3233/JAD-190258)

[Kim Y, et al. CSP in synaptic vesicle recycling. Autophagy. 2018](https://doi.org/10.1080/15548627.2018.1489465)

Mechanistic Role in Neurodegeneration

CSP in Synaptic Vesicle Cycling

The synaptic vesicle cycle is a highly coordinated process essential for neurotransmission. CSP plays critical roles at multiple stages:

Mermaid diagram (expand to render)

CSP in Protein Quality Control Network

CSP is an integral component of the neuronal protein quality control system:

Co-chaperone Function: The J-domain recruits Hsp70/Hsc70 to misfolded proteins

Substrate Recognition: The glycine-rich domain binds denatured proteins

Handoff to Degradation: CSP-Hsp70 complexes target irreversibly damaged proteins to:

[Proteasome](/mechanisms/proteasome-degradation) (ubiquitin-dependent)
[Lysosome](/mechanisms/autophagy-lysosome-neurodegeneration) (via chaperone-mediated autophagy)

CSP and Alpha-Synuclein Homeostasis

The relationship between CSP and [alpha-synuclein](/proteins/alpha-synuclein) is particularly relevant to [Parkinson's disease](/diseases/parkinsons-disease):

| Mechanism | Effect |
|-----------|--------|
| CSP deficiency | Enhanced α-syn oligomerization |
| CSP overexpression | Reduced α-syn aggregation |
| Autophagy regulation | CSP required for α-syn clearance |
| Hsp70 recruitment | CSP enhances Hsp70-mediated α-syn refolding |

ER-Mitochondria Contact Sites

CSP is enriched at mitochondria-associated membranes (MAMs), which are critical for:

Calcium signaling: ER-mitochondria Ca²⁺ transfer
Mitochondrial dynamics: Fission and fusion regulation
Lipid transfer: Phospholipid metabolism
Apoptosis regulation: Intrinsic pathway control

MAM dysfunction is implicated in both PD and AD, making CSP a key modulator of these disease processes.

Interaction Network

Protein-Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| Hsc70/Hspa8 | J-domain binding | Chaperone activity |
| Hsp40/DnaJB proteins | Co-chaperone complex | Client protein processing |
| Synaptotagmin | Calcium sensing | Synaptic vesicle fusion |
| SNARE proteins | Direct binding | Vesicle fusion |
| RyR | Calcium release | ER Ca²⁺ signaling |
| Mitochondrial proteins | Stress-induced | Oxidative stress protection |
| p62/SQSTM1 | Autophagy receptor | Selective autophagy |
| LC3/GABARAP | Autophagy | Lysosomal targeting |

Signaling Pathways

cAMP/PKA: Phosphorylation of CSP serine residues
Ca²⁺/Calmodulin: CSP-calmodulin interactions
MAPK/ERK: Stress-responsive phosphorylation
mTOR: Autophagy regulation of CSP levels

Clinical Perspectives

Biomarker Potential

CSP levels in cerebrospinal fluid (CSF) may serve as a biomarker:

Reduced CSP: Associated with ANCL and PD
CSF measurements: ELISA-based detection
Correlation with disease: Under investigation

Diagnostic Applications

Genetic testing: DNAJC5 sequencing for ANCL
Protein analysis: Western blot of patient samples
Functional assays: Chaperone activity measurements

Therapeutic Development

Chaperone-Based Approaches

| Strategy | Agent | Mechanism | Stage |
|----------|-------|-----------|-------|
| Pharmacological chaperone | 4-PBA | Protein stabilization | Preclinical |
| Hsp70 activator | Geranylgeranylacetone | Enhanced refolding | Preclinical |
| Autophagy inducer | Rapamycin | Enhanced clearance | Experimental |
| Autophagy activator | Trehalose | mTOR-independent | Preclinical |

Gene Therapy Approaches

AAV9-CSP: Preclinical rescue of phenotype
CRISPR-Cas9: Allele-specific editing for dominant mutations
siRNA: Knockdown of dominant-negative mutants

Historical Context

The discovery of CSP as a neuronal protein dates to the early 1990s. Key milestones:

1992: Initial characterization of cysteine string protein
1997: Demonstration of J-domain function (Chamberlain & Burgoyne)
2008: Crystal structure of J-domain resolved
2012: CSP knockout mice generated (Sharma et al.)
2016: DNAJC5 mutations cause ANCL (Cadzow et al.)
2020: CSP-alpha-synuclein interaction in PD (García-Partida et al.)

Research Gaps and Future Directions

Structural biology: High-resolution structure of full-length CSP

Client protein repertoire: Comprehensive identification of CSP substrates

Therapeutic development: Clinical trials for pharmacological chaperones

Biomarkers: Validation of CSP as disease biomarker

Disease mechanisms: Elucidating CSP's role in specific neurodegenerative diseases

📖 View canonical wiki page →

Related Entities

DNAJC5PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-dnajc5-protein
kg_node_id	DNAJC5PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1a202a8b542c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-dnajc5-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cysteine String Protein (CSP)

DNAJC5 Protein (Cysteine String Protein, CSP)

Introduction

DNAJC5 Protein (Cysteine String Protein, CSP)

Introduction

Protein Structure

J-Domain (Residues 1-70)

Glycine-Rich Linker (Residues 71-140)

Cysteine String Domain (Residues 141-198)

Molecular Function

Chaperone Activity

Synaptic Function

Calcium Homeostasis

Mitochondrial Function

Expression Pattern

Brain Regional Expression

Cellular Localization

Disease Associations

Adult-Onset Neuronal Ceroid Lipofuscinosis (ANCL)

Known Pathogenic Mutations

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis (ALS)

Therapeutic Targeting

Small Molecule Chaperones

Gene Therapy

Aggregation Inhibitors

Research Models

Animal Models

Cellular Models

Key Publications

See Also

External Links

References

Mechanistic Role in Neurodegeneration

CSP in Synaptic Vesicle Cycling

CSP in Protein Quality Control Network

CSP and Alpha-Synuclein Homeostasis

ER-Mitochondria Contact Sites

Interaction Network

Protein-Protein Interactions

Signaling Pathways

Clinical Perspectives

Biomarker Potential

Diagnostic Applications

Therapeutic Development

Chaperone-Based Approaches

Gene Therapy Approaches

Historical Context

Research Gaps and Future Directions

💬 Discussion